FDG-PET/CT Imaging in Chimeric Antigen Receptor-Engineered T-Cell Treatment in Patients with B-Cell Lymphoma: Current Evidence

[F-18]-FDG PET/CT stands as a cornerstone in the enhancement of patient care throughout all stages of CAR T-cell therapy. This review elucidates the substantial clinical utility of diverse biomarkers extracted from FDG PET such as glucose metabolism within tumor lesions and healthy tis-sues, including the liver and lymphoid structures. Prognostic and predictive markers obtained from baseline FDG PET offer insights into patient out-comes, enabling the identification of individuals who might derive long-term benefit most from CAR T-cell therapy. Early evaluations with FDGPET at 1 and 3 months posttreatment are para-mount for gauging response to therapy. Further-more, 2-Deoxy-2-[F-18]fluoroglucose ([F-18]-FDG)PET/CT shows potential in forecasting significant toxicities, with increasing interest in its application for brain scans to evaluate ICANS, underscoring its promise in advancing personalized treatment strategies in CAR T-cell therapy.